Review
Oncology
Juan Carlos Lopez-Gil, Laura Martin-Hijano, Patrick C. Hermann, Bruno Sainz Jr
Summary: This review summarizes the role of CXCL12 and its receptors in cancer stem cells and their niche, discusses therapeutic options, and highlights the need for a comprehensive review on the topic.
Article
Hematology
Xiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, Patricia Muschong, Elisabeth Bayer, Romina J. Walter, Julia C. Gutjahr, Richard Greil, Miguel L. Conch, Carsten Mueller-Tidow, Tanja N. Hartmann, Veronique Orian-Rousseau
Summary: CD44 plays a crucial role in resistance to venetoclax-based therapies in AML, affecting the effects of CXCL12 and the expression of stem cell core transcription factors.
Article
Medicine, Research & Experimental
Mei Zheng, Sang Ho Oh, Nahyun Choi, Yong Jin Choi, Jino Kim, Jong-Hyuk Sung
Summary: This study reveals that CXCL12 inhibits hair growth through the CXCR4/STAT signaling pathway, and inhibitors of the CXCL12/CXCR4 pathway show promise as a treatment option for hair growth.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cell Biology
Xue Wu, Lu Qian, Huadong Zhao, Wangrui Lei, Yanqing Liu, Xiaoling Xu, Jiawen Li, Zhi Yang, Du Wang, Yuchen Zhang, Yan Zhang, Ran Tang, Yang Yang, Ye Tian
Summary: Fibrosis is a pathological process caused by abnormal wound healing response, leading to excessive deposition of extracellular matrix, distortion of organ architecture, and loss of organ function. CXCL12/CXCR4 play various roles in the pathological mechanisms of fibrosis and have been shown to improve fibrosis levels in multiple organs.
AGEING RESEARCH REVIEWS
(2023)
Article
Oncology
Tomokatsu Kato, Yoichi Matsuo, Goro Ueda, Hiromichi Murase, Yoshinaga Aoyama, Kan Omi, Yuichi Hayashi, Hiroyuki Imafuji, Kenta Saito, Mamoru Morimoto, Ryo Ogawa, Hiroki Takahashi, Shuji Takiguchi
Summary: The study found that CXCR4 is highly expressed in radiation-resistant PaCa cells, and the CXCL12/CXCR4 axis may be involved in the radiation resistance of PaCa. Treatment with a CXCR4 antagonist can suppress the invasion ability of radiation-resistant PaCa cells, aiding in the inhibition of cell colonization.
Article
Pharmacology & Pharmacy
Riccardo Capecchi, Cristina Croia, Ilaria Puxeddu, Federico Pratesi, Andrea Cacciato, Daniela Campani, Ugo Boggi, Luca Morelli, Antonio Tavoni, Paola Migliorini
Summary: The study revealed significantly higher levels of serum SDF-1/CXCL12 in IgG4-RD patients compared to normal controls, suggesting a potential role of this chemokine in the pathogenesis of IgG4-RD. Additionally, the IgG4-RD AIP subgroup showed higher serum levels of SDF-1/CXCL12 compared to the SSj group.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Xiao-Hui Wang, Shu-Feng Zhang, Hai-Ying Wu, Jian Gao, Xu-Hui Wang, Tian-Hui Gao
Summary: Our study reveals that the expression of SOX17 is repressed in neuroblastoma tissues and cells, and that SOX17 suppresses NB tumor formation and proliferation through inhibition of the CXCL12/CXCR4 signaling pathway.
CELLULAR SIGNALLING
(2021)
Review
Biochemistry & Molecular Biology
Yaru Yang, Jiayan Li, Wangrui Lei, Haiying Wang, Yunfeng Ni, Yanqing Liu, Huanle Yan, Yifan Tian, Zheng Wang, Zhi Yang, Shulin Yang, Yang Yang, Qiang Wang
Summary: Cancer is a complex disease caused by genetic mutations and/or epigenetic changes, and it poses the biggest challenge worldwide. Cytokines, particularly chemokines, play a significant role in various human cancers by affecting homeostasis, immune function, and facilitating cancer development stages such as invasion, metastasis, and angiogenesis. Specifically, chemokines such as CXCL12 and its receptors CXCR4 and CXCR7 exert extensive influence on tumor cell behavior, including proliferation, survival, angiogenesis, metastasis, and tumor microenvironment, making them crucial players in the initiation and progression of cancers such as leukemia, breast cancer, lung cancer, prostate cancer, and multiple myeloma. This review aims to summarize the recent research progress and future challenges related to the CXCL12-CXCR4/CXCR7 signaling axis in cancer, emphasizing the potential of utilizing CXCL12-CXCR4/CXCR7 as a biomarker or therapeutic target for cancer treatment and providing valuable insights for the development of targeted cancer therapies.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Cell Biology
Kathryn E. Luker, Gary D. Luker
Summary: This study reveals the regulation of PKM2 and cellular metabolism by CXCL12 signaling through CXCR4 and ACKR3, leading to the dissociation of PKM2 from beta-arrestin 2 and a shift in its oligomerization state.
Article
Multidisciplinary Sciences
Alexander M. Hilla, Annemarie Baehr, Marco Leibinger, Anastasia Andreadaki, Dietmar Fischer
Summary: Regenerative failure in the optic nerve is attributed to a chemoattractive CXCL12/CXCR4-dependent mechanism that prevents growth-stimulated axons from regenerating distally. Depletion of CXCR4 or CXCL12 reduces aberrant axonal growth and enables long-distance regeneration.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Dermatology
Hui Fang, Ke Xue, Tianyu Cao, Qingyang Li, Erle Dang, Yanghe Liu, Jieyu Zhang, Pei Qiao, Jiaoling Chen, Jingyi Ma, Shengxian Shen, Bingyu Pang, Yaxing Bai, Hongjiang Qiao, Shuai Shao, Gang Wang
Summary: Bullous pemphigoid (BP) is an autoimmune bullous skin disease characterized by autoantibodies against skin proteins. B-cell-targeting biologics have shown effectiveness in BP, indicating the role of B cells in its pathogenesis. In this study, researchers found that the CXCL12/CXCR4 axis plays a pathogenic role in modulating B-cell trafficking and differentiation in BP, and targeting CXCR4 could be a potential strategy for BP treatment.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Seong-Kyu Kim, Jung-Yoon Choe, Ki-Yeun Park
Summary: The study aimed to investigate the expression of CXCR4 and CXCL12 in gout patients and its involvement in uric acid-induced inflammation. Serum levels of IL-1 beta, IL-18, CXCL12, and CXCR4 were measured in 40 gout patients and 27 controls. U937 cells treated with monosodium urate crystals were used to assess the gene and protein expressions of these molecules. The results showed higher levels of IL-1 beta, IL-18, and CXCL12 in gout patients, and the serum CXCR4 level was associated with IL-18 level, uric acid level, and uric acid/creatinine ratio. The study revealed the role of CXCL12 and CXCR4 in the pathogenesis of uric acid-induced inflammation and gouty arthritis.
Article
Hematology
Marta Biondi, Sarah Tettamanti, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Rocco Piazza, Samantha Donsante, Simone Bido, Vincenzo Maria Perriello, Vania Broccoli, Andrea Doni, Francesco Dazzi, Alberto Mantovani, Gianpietro Dotti, Andrea Biondi, Alice Pievani, Marta Serafini
Summary: Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal clonal proliferation and differentiation. The efficacy of chimeric antigen receptor (CAR)-T-cell therapy in AML has been hindered by factors such as poor accumulation in the leukemia bone marrow niche. Overexpression of CXCR4 in CAR-T cells may improve T-cell homing to the bone marrow and enhance their contact with AML cells, potentially increasing their therapeutic potential. In conclusion, arming CAR-T cells with CXCR4 represents a promising strategy for AML treatment.
Article
Hematology
Julian Leberzammer, Stijn M. Agten, Xavier Blanchet, Rundan Duan, Hans Ippel, Remco T. A. Megens, Christian Schulz, Maria Aslani, Johan Duchene, Yvonne Doring, Natalie J. Jooss, Pengyu Zhang, Richard Brandl, Konstantin Stark, Wolfgang Siess, Kerstin Jurk, Johan W. M. Heemskerk, Tilman M. Hackeng, Kevin H. Mayo, Christian Weber, Philipp von Hundelshausen
Summary: The study explored the molecular mechanisms of CXCL12 in arterial thrombosis, revealing that inhibition of CXCR4 can attenuate platelet aggregation and limit arterial thrombosis. Mechanistically, CXCL12 activates Btk leading to platelet aggregation, while the interaction between CXCL12 and CCL5 can inhibit this process. A novel peptide was found to inhibit CXCL12-induced platelet aggregation without prolonging bleeding time.
Article
Oncology
Ruozheng Wei, Yuning Zhou, Chang Li, Piotr Rychahou, Shulin Zhang, William B. Titlow, Greg Bauman, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Heidi L. Weiss, B. Mark Evers, Qingding Wang
Summary: This study identifies ketogenesis as a critical regulator of the tumor microenvironment in colorectal cancer and suggests the potential for ketogenic diets as a metabolic strategy to overcome immunosuppression and prolong survival.
